BioSpace News Archive

Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications, reported pipeline highlights and first quarter financial results.

TScan Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Walden Biosciences, Inc. announced that it has entered into a research collaboration with Primula Group to lever a large body of genetic data on patients living with chronic kidney disease, including insights from close to 500,000 individuals in the UK Biobank.

Ovid Therapeutics Inc., a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.

Tiziana Life Sciences, Ltd. announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis.

Fulcrum Therapeutics, Inc.® reported financial results for the first quarter of 2024 as well as an update to the business.

Entera Bio Ltd., a leader in the development of orally delivered peptides and small therapeutic proteins, announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts.

Medicenna Therapeutics Corp. announced that the American Society of Clinical Oncology decided to reverse its decision and to withdraw Medicenna’s abstract entitled “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors,” which had been initially selected for an oral podium presentation at ASCO’s 2024 Annual Meeting.

The 2024 American Society of Clinical Oncology Annual Meeting will be held in Chicago from May 31 to June 4, 2024.

QIAGEN announced that the U.S. Food and Drug Administration has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.